Orsiro - the first hybrid drug-eluting stent, opening up a new class of drug-eluting stents for superior patient outcomes

Interventional Cardiology: Reviews, Research, Resources

Volumn 6, Issue 2, 2011, Pages 142-144

  Tittelbach, Michael ^a   Diener, Tobias ^a  

^a Biotronik   (Switzerland)

Author keywords

BIOlute active coating; Coronary artery stenosis; Drug eluting stent; Hybrid; Orsiro; PRO kinetic energy platform; PROBIO passive coating

Indexed keywords

ARTICLE; BIOCOMPATIBILITY; CORONARY ARTERY DISEASE; DEVICE SAFETY; DRUG ELUTING STENT; HUMAN; MATERIAL COATING; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 85017406459     PISSN: 17561477     EISSN: 17561485     Source Type: Journal    
DOI: 10.15420/icr.2011.6.2.142     Document Type: Article

References (8)

1. Kalnins A, Erglis U, Dinne A, et al. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease, Med Sci Monit, 2002;8:16-20
2. Amon M, Bolz A, Schaldach M, Improvement of stenting therapy with a silicon carbide coated tantalum stent, J Mat Sci Materials in Med, 1996;7:273-8
3. Fan W, Johnson DM, Feldman MD, et al. Metallic stents coated with bioabsorbable polymers, Cardiac Interventions Today, 2009;7:42-9
4. Zilberman M, Eberhart RC, Drug-eluting bioresorbable stents for various applications, Annu Rev Biomed Eng, 2006;8:153-80
5. Fischell TA, Dishmon D, Elhaddi A, et al. The perfect drugeluting stent, Cardiac Interventions Today, 2009;7:29-36
6. Parry TJ, Brosius R, Thyagarajan R, et al. Drug eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries, Eur J Pharmacol, 2005;524:19-29
7. Wessely R, Blaich B, Belaiba RS, et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery, Thromb Haeomst, 2007;97;1003-12
8. Hamon M, First-in-man experience with the DES Orsiro in the treatment of patients with single de novo coronary artery lesions (BIOFLOW-I), Late breaking first-in-human trials session, EuroPCR 2011, Paris, May 18 2011